Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) will almost certainly enjoy huge revenue growth this year. Their respective coronavirus vaccines have already been given to millions of people in the U.S. and other countries. Billions of dollars will soon flow into the drugmakers’ coffers.
Both of the stocks could deliver solid gains in the coming months. However, I think there are two COVID-19 vaccine stocks that could be much-bigger winners. Here’s why Novavax (NASDAQ: NVAX) and Vaxart (NASDAQ: VXRT) could trounce both Pfizer and Moderna in 2021.